The law, slated to take effect in September, requires health plans to cover the treatment given by in-network providers, not ...

Using 400 real-world patient cases, the CARE platform correctly classified 99.5 percent of cases according to NCCN guidelines ...

NEW YORK – The European Commission has granted conditional approval to Jazz Pharmaceuticals' Ziihera (zanidatamab) for previously treated patients with unresectable, locally advanced or metastatic ...

NEW YORK – Ensem Therapeutics on Tuesday said it dosed the first patient in a Phase I/II trial of the mutant-selective PI3kα inhibitor ETX-636 in patients with solid tumors. ETX-636 is designed to ...

NEW YORK – Neurogene this week said it has taken steps to begin a registrational trial to evaluate NGN-401, its investigational gene therapy for Rett syndrome, after reaching an agreement with the US ...

NEW YORK – The US Food and Drug Administration on Wednesday granted accelerated approval to Dizal's oral EGFR inhibitor Zegfrovy (sunvozertinib) as a treatment for patients with locally advanced or ...

The study will use a companion lipid biomarker test to identify those with a poor prognosis who are potential best responders.

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.

The study also included older children and found the best outcomes in patients between 5 years and 8 years old.

D Molecular Therapeutics said it is streamlining operations to offset expected expenses as it accelerates the timelines for its Phase III trials.

A legislative ban on pharma ads, a tool for companies to amplify messaging on drugs, including for precision medicines, is ...